Why the study?
Do platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2 G-765C) polymorphisms correlate with antiplatelet response in patients treated with aspirin?
Do platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2 G-765C) polymorphisms correlate with antiplatelet response in patients treated with aspirin?
GPIba C-5T was associated with aspirin response variability; leaves open whether genotyping improves resistance prediction in practice.
Aspirin is an antiplatelet agent commonly used in treatment of patients with high risk to develop stroke and myocardial infarction. However, interindividual variability regarding the inhibition of platelet function by aspirin is well documented. In this study, the correlation between platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2 G-765C) polymorphisms and antiplatelet response in patients treated with aspirin was investigated.
No takes yet. Share an insight, caveat, or question.
Al‐Azzam et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: